申请人:Societa' Farmaceutici Italia S.p.A.
公开号:US04141899A1
公开(公告)日:1979-02-27
New 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine derivatives are disclosed, and more particularly derivatives of Formula I ##STR1## where R.sub.1 is hydrogen or an alkyl having from 1 to 4 carbon atoms; R.sub.2 is hydrogen, an alkyl having from 1 to 4 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, phenyl or a heterocycle; R.sub.3 is hydrogen, a saturated or unsaturated straight or branched alkyl having from 1 to 6 carbon atoms, a cycloalkyl having from 3 to 6 carbon atoms, benzoyl or phenyl; and X is O, S or NR.sub.4 where R.sub.4 is hydrogen, an alkyl having from 1 to 4 carbon atoms, cyano, amino, nitro or acylamino; Or pharmaceutically acceptable acid addition salts thereof. Also disclosed is a process of preparing these compounds which comprises condensing an appropriate 4,5,6,7-tetrahydroimidazo-[4,5-c]-pyridine with an appropriate alkyl isocyanate, alkyl isothiocyanate or substituted S-methyl thiourea, preferably in a solvent such as ethanol, acetonitrile or dioxane, usually under reflux for from 4 to 12 hours. The products can be isolated by crystallization as free bases or as salts of pharmaceutically acceptable acids. The new compounds have proved to be well tolerated and to inhibit both the number of experimental ulcers and the gastric secretion in experimental animals. Thus, they should prove useful in the therapy of gastric and duodenal ulcers in man.
本文揭示了新的4,5,6,7-四氢咪唑[4,5-c]-吡啶衍生物,更具体地是公式I的衍生物:##STR1## 其中R.sub.1为氢或具有1至4个碳原子的烷基;R.sub.2为氢、具有1至4个碳原子的烷基、具有3至6个碳原子的环烷基、苯基或杂环基;R.sub.3为氢、具有1至6个碳原子的饱和或不饱和直链或支链烷基、具有3至6个碳原子的环烷基、苯甲酰基或苯基;X为O、S或NR.sub.4,其中R.sub.4为氢、具有1至4个碳原子的烷基、氰基、氨基、硝基或酰胺基;或其药学上可接受的酸盐。还揭示了制备这些化合物的过程,包括将适当的4,5,6,7-四氢咪唑[4,5-c]-吡啶与适当的烷基异氰酸酯、烷基异硫氰酸酯或取代的S-甲基硫脲缩合,通常在乙醇、乙腈或二恶英等溶剂中回流4至12小时。产物可以通过结晶作为自由碱基或药学上可接受的酸盐分离。新化合物被证明耐受性良好,并且在实验动物中抑制溃疡数量和胃分泌物。因此,它们应该在治疗人类胃十二指肠溃疡方面证明有用。